Page 63 - Read Online

Ballarò et al. J Cancer Metastasis Treat 2019;5:61 I http://dx.doi.org/10.20517/2394-4722.2019.003 Page 7 of 9

DECLARATIONS
Authors’ Contributions
Wrote the manuscript: Ballarò R
Discussed and revised the manuscript: Penna F, Ferraro E, Costelli P

Availability of data and materials
Not applicable.

Financial Support and Sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical Approval and Consent to Participate
Not applicable.

Consent for Publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Prim 2018;4:1-18.
2. von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts
and numbers update 2016. J Cachexia Sarcopenia Muscle 2016;7:507-9.
3. Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, et al. Why cachexia kills: Examining the causality of poor outcomes in
wasting conditions. J Cachexia Sarcopenia Muscle 2013;4:89-94.
4. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, et al. Cachexia:a new definition. Clin Nutr 2008;27:793-9.
5. Pin F, Couch ME, Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body
composition. Curr Opin Support Palliat Care 2018;12:420-6.
6. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer
2014;14:754-62.
7. Penna F, Ballarò R, Martinez-cristobal P, Sebastian D, Busquets S, et al. Autophagy exacerbates muscle wasting in cancer cachexia
and impairs mitochondrial function. J Mol Biol 2019;2674-86.
8. Penna F, Costamagna D, Pin F, Camperi A, Fanzani A, et al. Autophagic degradation contributes to muscle wasting in cancer
cachexia. Am J Pathol 2013;182:1367-78.
9. Penna F, Bonetto A, Aversa Z, Minero VG, Rossi Fanelli F, et al. Effect of the specific proteasome inhibitor bortezomib on cancer-
related muscle wasting. J Cachexia Sarcopenia Muscle 2015;7:345-54.
10. Penna F, Ballarò R, Beltrá M, Lucia S De, Costelli P. Modulating metabolism to improve cancer-induced muscle wasting. Oxid Med
Cell Longev 2018;2018:7153610.
11. von Meyenfeldt M. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 2005;9:35-8.
12. Collins P, Bing C, McCulloch P, Williams G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal
adenocarcinoma in humans. Br J Cancer 2002;86:372-5.
13. Julienne CM, Dumas JF, Goupille C, Pinault M, Berri C, et al. Cancer cachexia is associated with a decrease in skeletal muscle
mitochondrial oxidative capacities without alteration of ATP production efficiency. J Cachexia Sarcopenia Muscle 2012;3:265-75.
14. Busquets S, Almendro V, Barreiro E, Figueras M, Argilés JM, et al. Activation of UCPs gene expression in skeletal muscle can be
independent on both circulating fatty acids and food intake: Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett
2005;579:717-22.
15. Argilés JM, López-Soriano FJ, Busquets S. Muscle wasting in cancer: the role of mitochondria. Curr Opin Clin Nutr Metab Care
2015;18:221-5.
16. Brown JL, Rosa-Caldwell ME, Lee DE, Blackwell TA, Brown LA, et al. Mitochondrial degeneration precedes the development of
muscle atrophy in progression of cancer cachexia in tumour bearing mice. J Cachexia Sarcopenia Muscle 2017;8:926-38.